The top analyst upgrades, downgrades and initiations seen on Tuesday morning include AK Steel, Celgene, Darden Restaurants, Delphi Automotive, Johnson & Johnson and U.S. Steel.
November 28, 2016: Markets opened lower Monday after a long weekend of eating and shopping. There was no economic news of note, so this may just be a pause in an equity…
Solar energy adoption among large U.S. corporations has grown from a total installed base of 300 megawatts (MW) in 2012 to more than 1,000 MW this year. The total represents 16% of…
Outside of Warren Buffett being one of the richest men alive and being considered the greatest investor of modern times, there have been many key changes in the Buffett stocks over recent…
With the busiest earnings week behind us, it appears some of the restriction windows at major U.S. corporations are starting to open up a little.
Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.
Of the 30 Dow Jones Industrial Average stocks, only five of them have outperformed analyst expectations this year, though some have outperformed analyst expectations handily.
Johnson & Johnson released a better-than-expected third-quarter report before the markets opened on Tuesday.
Chris Lange Johnson & Johnson is expected to release its most recent earnings report before the markets open on Tuesday.
Chris Lange A third of the Dow Jones Industrial Average is reporting quarterly results this week, which has the potential to push the Dow back up to its highs.
Here are four Dow stocks that have raised their dividends for 50 years or more, and that also appear to be able to keep raising their dividends in the years ahead.
These corporate giants have stated or admitted on their own that they are in the 25-year dividend hike game.
A unit of Johnson & Johnson has announced that the FDA has approved its Stelara for the treatment of moderately to severely active Crohn's disease.
Jon C. Ogg Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.
